Mometasone furoate dry powder inhaler for the treatment of asthma

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Introduction: Asthma is a chronic inflammatory disease that causes significant morbidity and mortality. Inhaled corticosteroids are the preferred initial treatment for this disorder. Mometasone furoate dry powder is an inhaled corticosteroid that is approved for once-daily treatment of asthma in both adults and children as young as 4 years. Areas covered: The goal of this paper is to review the clinical efficacy and safety of mometasone furoate dry powder inhaler for the treatment of asthma. A literature search using PubMed was done using the terms 'mometasone furoate', 'inhaled corticosteroid' and 'asthma', focusing on articles that highlighted clinical trials and addressed efficacy of the medication. Expert opinion: Mometasone furoate dry powder inhaler has an excellent safety and efficacy profile. For patients with persistent asthma who require treatment with an inhaled corticosteroid, mometasone furoate is an excellent therapeutic choice.

Original languageEnglish (US)
Pages (from-to)2707-2712
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number17
DOIs
StatePublished - Dec 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Mometasone furoate dry powder inhaler for the treatment of asthma'. Together they form a unique fingerprint.

Cite this